Clinical Trial
Postoperative Radiotherapy in Women with Early Operable Breast Cancer (Scottish Breast Conservation Trial): 30-year Update of a Randomized, Controlled, Phase 3 Trial.
Williams et al. Lancet Oncology 25(9):1213-1221, 2024.
The study followed 585 women with early-stage breast cancer for up to 30 years to examine the effects of radiotherapy. The 30-year overall survival rates were similar, at 19.2% for the radiotherapy group and 18.7% for those not receiving radiotherapy. Breast cancer-related deaths were lower in the radiotherapy group (37%) compared to 46% in the non-radiotherapy group. However, non-breast cancer-related deaths were higher in the radiotherapy group (20%) than in the non-radiotherapy group (11%). The study suggested that while radiotherapy reduces local cancer recurrence, it does not significantly enhance long-term survival rates and is associated with increased non-cancer-related mortality.
https://www.instagram.com/p/C_WWxO5peyr/
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge et al. N Engl J Med. 388(18):1645-1656, 2023.
This multi-institutional prospective study was designed to assess the risk of breast cancer recurrence in patients with HR-positive early breast cancer (median age 37 years) who choose to halt their endocrine therapy to pursue pregnancy temporarily. Overall, the study concluded no additional short-term risk of breast cancer recurrence in such temporary interruption of endocrine therapy compared to the control group.
https://pubmed.ncbi.nlm.nih.gov/37133584/
Accelerated Partial Breast Irradiation Using Sole Interstitial Multi-catheter Brachytherapy Compared with Whole-breast Irradiation with Boost for Early Breast Cancer: 10-year Results of a GEC-ESTRO Randomized, Phase 3, Non-inferiority Trial.
Groupe Européen de Curiethérapie et al., Lancet Oncology pii: S1470-
2045(23)00018-9, 2023.
The use of radiotherapy after breast-conserving surgery is a commonly used treatment protocol. To minimize the toxicity associated with whole-breast irradiation, this study conducted a phase 3 randomized trial involving accelerated partial breast irradiation (APBI) multi-catheter brachytherapy (n=633) and a cohort of whole-breast irradiation (n=551) with follow-up studies for 10-year. The authors concluded that using APBI multi-catheter brachytherapy is an alternative option to reduce later side effects compared to the whole-breast irradiation procedure in post-operative patients with early breast cancer.
https://pubmed.ncbi.nlm.nih.gov/36738756/
Adjuvant Endocrine Therapy Non-initiation and Non-persistence in Young Women with Early stage Breast Cancer.
Rosenberg et al., Breast Cancer Res Treat. 197(3):547-558, 2023.
The goal of this study was to design better strategies to improve adherence to adjuvant endocrine therapy (ET) by learning from the experience of two groups of younger women with breast cancer, those taking no adjuvant endocrine therapy for 18 months post-diagnosis and the second group included women who started on ET but informed not continuing for a period of 5-year after diagnosis. Based on the data and associated analysis, the article presents pathways that could be used for making a timely decision about the utility of ET to improve BCYW survivors’ adherence to recommended endocrine therapies.
https://pubmed.ncbi.nlm.nih.gov/36436128/
Abemaciclib plus Endocrine Therapy for Hormone Receptor-positive, HER2-negative, Node-positive, High-risk Early Breast Cancer (monarchE): Results from a Preplanned Interim Analysis of a Randomized, Open-label, Phase 3 trial.
Johnston et al., Lancet Oncology 24(1):77-90, 2023.
This interim report discusses an open-label, randomized phase 3 trial involving young patients with early breast cancer (>18-yr) with a high recurrence risk and (aged ≥18 years) and treatment with adjuvant abemaciclib plus endocrine therapy. Data suggested that using abemaciclib in an adjuvant setting lowers the risk of recurrence of hormone receptor-positive and HER2-negative breast cancer.
https://pubmed.ncbi.nlm.nih.gov/36493792/
Impact of Stromal Tumor-infiltrating Lymphocytes (sTILs) on Response to Neoadjuvant Chemotherapy in Triple-negative Early Breast Cancer in the WSG-ADAPT TN Trial.
Kolberg-Liedtke et al., Breast Cancer Research 24(1):58, 2022.
This study examined the influence of stromal tumor-infiltrating lymphocytes (sTILs) in pathological complete response (pCR) in patients with triple-negative breast cancer after undergoing neoadjuvant chemotherapy. The study suggested that the nature of immune response could influence biological pathways involved in long-term survival, and the TNBC cases could be further sub-grouped based on immune and other components.
https://pubmed.ncbi.nlm.nih.gov/36056374/
Antiprogestins Reduce Epigenetic Field Cancerization in Breast Tissue of Young Healthy Women.
Bartlett et al., Genome Medicine 14(1):64, 2022.
This article examined the effect of impairing progesterone signaling in biological characteristics which collectively drive breast cancer development. The study focused on premenopausal health women donors with and without a BRCA mutation, normal breast tissues from cases with no family history of breast, specimens from triple-negative breast cancer diagnosis, or matching adjacent tissues, etc. The article reports an elevation in progesterone levels during the menstrual cycle in cases with BRCA mutations, implying a role of interfering with progesterone signaling in a subset of breast cancer patients.
https://pubmed.ncbi.nlm.nih.gov/35701800/
News & Updates
Connect With Us
